Search for a report

GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028

  • You are here:
  • Home
  • Downloads
  • GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028

GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028

The global molecular point of care diagnostics market is estimated to grow with a CAGR of 14.90% by revenue, during the year 2019-2028.  The market is anticipated to acquire a revenue of about $8382.15 Million by 2028.  The base year considered for the study is 2018. The projected period is between 2019 and 2028. Currently, the market is majorly driven by the need for diagnosing SARS-CoV-2 patients. As of now, there are no treatments available, and the best possible solution is hindering the spread of the disease. Several countries have locked their borders.

GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET FORECAST 2019-2028

Global Molecular Point of Care Diagnostics Market by Technology (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification Technology, Other) by Product (Assays, Instruments, Software)  by Application (Infectious Disease, Oncology, Prenatal, Others) by End-user (Hospitals, Clinics, Diagnostics Centres, Others) and by Geography.

Request free sample

The global molecular point of care diagnostics market is estimated to grow with a CAGR of 14.90% by revenue, during the year 2019-2028.  The market is anticipated to acquire a revenue of about $8382.15 Million by 2028.  The base year considered for the study is 2018. The projected period is between 2019 and 2028.

The market growth is propelled by the following factors:

  • Demand from governments for diagnosing COVID-19 positive patients
  • Rise in demand for non-invasive diagnosis
  • Growth in the number of diseases
  • Funding for research and development
  • Technological advancements in the market

Global Molecular Point of Care Diagnostics Market

To know more about this report, request a free sample copy

Currently, the market is majorly driven by the need for diagnosing SARS-CoV-2 patients. As of now, there are no treatments available, and the best possible solution is hindering the spread of the disease. Several countries have locked their borders. The incubation period for the disease is 14 days (i.e., the symptoms appear after 14 days being infected by the disease). Hence, the late diagnosis will lead to more spread. Sending samples to the labs and receiving the results takes time. And when it involves a large number of people, it becomes much more difficult for government authorities. Hence, a molecular point of care diagnostic technique becomes a good solution for early detection of the disease.

In the technology segment, the Polymerase Chain Reaction (PCR) technology captured the largest market share of 73.92% in 2019. It is also evaluated to be the fastest-growing technology growing with a CAGR of 15.36%. The PCR technology helps researchers to amplify small amounts of DNA to concentrations that can be used for analysis. Due to its efficient detection of biomarkers, the PCR-based molecular diagnostics point of care market is expected to continue dominating market share in infectious diseases, oncology, and other chronic diseases. PCR-based molecular diagnostic point of care has seen substantial growth due to many approvals, including the FDA approvals of PCR-based molecular diagnostic point of care. The PCR technology has two types, Real-time PCR and Digital PCR, of which Real time PCR is the dominant technology.

The restraining factors of market growth are the high capital requirements and a lack of high complexity testing centers. Costly instruments are the prime contributing factor to the high demand for money. The size of the capital investment required, therefore, varies, depending on the size and abilities of the developed laboratory. Additionally, with the continuing rapid advances, new genomic platforms need significant capital expenditure and a usually high volume test to allow activity at scale and attain competitive prices.

The report on the global molecular point of care diagnostics market includes the segmentation analysis of product, application, technology, and end-user.

Market by Product:

  • Assays
  • Instruments
  • Software

Market by Application:

  • Infectious Disease
    • Respiratory
    • Hospital Acquired Infections
    • Sexually Transmitted Infections
    • Gastro Intestinal infections
  • Oncology
  • Prenatal
  • Others

Market by Technology:

  • Polymerase Chain Reaction
    • Real-time PCR (q-PCR)
    • Digital PCR (d-PCR)
  • Isothermal Nucleic Acid Amplification Technology
  • Other

Market by End-user:

  • Hospital
  • Clinics
  • Diagnostic Centers
  • Others

Geographically, the global molecular point of care diagnostics market has been segmented on the basis of four major regions, which includes:

  • North America: the United States and Canada
  • Europe: the United Kingdom, Germany, France, Italy, Russia, Belgium, Poland, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia Pacific
  • Rest of World: Latin America, the Middle East & Africa

Geographically, the North America region dominated the global molecular point of care diagnostics market in 2019, capturing a market share of 42.04%. The market in the region is majorly driven by various technological innovations to advance and enhance the overall scope of molecular diagnostics. These advanced research and development projects, particularly focused upon genetics and pharmacogenomics, have further aided in understanding the biology of infectious diseases, various types of cancer, and inherited diseases.

At the same time, the Asia Pacific region is anticipated to be the fastest-growing region during the forecast period growing with an anticipated CAGR of 15.33%. The Asia Pacific region has been witnessing tremendous growth in precision medicine technology. Several initiatives have been undertaken in this region to promote research and development on precision medicine solutions for better patient health. In order to facilitate access to precision medicine technologies and to address regulatory and funding issues, regulatory authorities, pharmaceutical industry, diagnostic companies, and service providers, are collaborating to provide an international platform for harmonized protocols.

The major market players in the global molecular point of care diagnostics market include:

  • Abbott Laboratories
  • BioMérieux SA
  • F Hoffmann-La Roche AG
  • Quidel Corporation
  • Hologic Inc
  • Qiagen NV
  • Others

Company Profiles covers the analysis of important players. These companies are using organic and inorganic strategies for growth. For instance, in April 2020, Biocartis NV announced the expansion of its partnership with Immunexpress. In March 2020, Abbot Laboratories launched the molecular point of care test to detect SARS-CoV-2 in a patient. In March 2020, The Luminex Corp received $642,450 in funding from the Biomedical Advanced Research and Development Authority (BARDA).

Key findings of the global molecular point of care diagnostics market are:

  • The rising geriatric population is responsible for the increasing demands in the market.
  • There is a growing prevalence of target diseases.
  • FDA’S Emergency Use Authorization (EUA) for molecular POC diagnostics helps for speedy deployment of products.
  • The North America region garners the largest market share.
  • There are growth opportunities for molecular point of care diagnostic products in emerging nations.
  • The hybridization of available technologies shows promising trends in the market.
  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    •    KEY DRIVERS
      • DEMAND FROM GOVERNMENTS FOR DIAGNOSING COVID-19 POSITIVE PATIENTS
      • RISE IN DEMAND FOR NON-INVASIVE DIAGNOSIS
      • GROWTH IN THE NUMBER OF DISEASES
      • FUNDING FOR RESEARCH AND DEVELOPMENT
      • TECHNOLOGICAL ADVANCEMENTS IN THE MARKET
    •    KEY RESTRAINTS
      • HIGH CAPITAL REQUIREMENT
      • LACK OF HIGH COMPLEXITY TESTING CENTERS
  1. KEY ANALYTICS
    • KEY INVESTMENT INSIGHTS
    •    PORTER’S FIVE FORCE ANALYSIS
      • BUYER POWER
      • SUPPLIER POWER
      • SUBSTITUTION
      • NEW ENTRANTS
      • INDUSTRY RIVALRY
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    •    REGULATORY FRAMEWORK
      • UNITED STATES
      • EUROPE
      • ASIA-PACIFIC
  1. MARKET BY TECHNOLOGY
    •    POLYMERASE CHAIN REACTION
      • REAL TIME PCR
      • DIGITAL PCR
    • ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • OTHER
  2. MARKET BY PRODUCT
    • ASSAYS
    • INSTRUMENTS
    • SOFTWARE
  3. MARKET BY APPLICATION
    •    INFECTIOUS DISEASE
      • RESPIRATORY
      • HOSPITAL ACQUIRED INFECTIONS
      • SEXUALLY TRANSMITTED INFECTIONS
      • GASTRO INTESTINAL INFECTIONS
    • ONCOLOGY
    • PRENATAL
    • OTHERS
  4. MARKET BY END-USER
    • HOSPITALS
    • CLINICS
    • DIAGNOSTICS CENTRES
    • OTHERS
  5. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • UNITED STATES
      • CANADA
    •    EUROPE
      • UNITED KINGDOM
      • GERMANY
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • INDONESIA
      • THAILAND
      • VIETNAM
      • AUSTRALIA & NEW ZEALAND
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • ABBOTT LABORATORIES
    • ABACUS DIAGNOSTICA
    • BIOMÉRIEUX SA
    • BIOCARTIS NV
    • DANAHER CORPORATION
    • DIASORIN SPA
    • BIO-RAD
    • F HOFFMANN-LA ROCHE AG
    • LUMINEX CORPORATION
    • HOLOGIC INC
    • MESA BIOTECH
    • SPARTAN BIOSCIENCES INC
    • QUANTUMDX GROUP LTD
    • QUIDEL CORPORATION
    • QIAGEN NV

TABLE LIST

TABLE 1: MARKET SNAPSHOT – MOLECULAR POINT OF CARE DIAGNOSTICS

TABLE 2: EMERGENCY USE AUTHORISATION FOR DIAGNOSTICS BY FDA

TABLE 3: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 4: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 5: GLOBAL POLYMERASE CHAIN REACTION MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 6: GLOBAL POLYMERASE CHAIN REACTION MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 7: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 8: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 9: GLOBAL REAL TIME PCR MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 10: GLOBAL REAL TIME PCR MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 11: GLOBAL DIGITAL PCR MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 12: GLOBAL DIGITAL PCR MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 13: GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 14: GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 15: GLOBAL OTHER MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 16: GLOBAL OTHER MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 17: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 18: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 19: GLOBAL ASSAYS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 20: GLOBAL ASSAYS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 21: GLOBAL INSTRUMENTS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 22: GLOBAL INSTRUMENTS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 23: GLOBAL SOFTWARE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 24: GLOBAL SOFTWARE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 25: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 26: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 27: GLOBAL INFECTIOUS DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 28: GLOBAL INFECTIOUS DISEASE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 29: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 30: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 31: GLOBAL RESPIRATORY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 32: GLOBAL RESPIRATORY DISEASE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 33: GLOBAL HOSPITAL ACQUIRED INFECTIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 34: GLOBAL HOSPITAL ACQUIRED INFECTIONS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 35: GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 36: GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 37: GLOBAL GASTRO INTESTINAL INFECTIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 38: GLOBAL GASTRO INTESTINAL INFECTIONS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 39: GLOBAL ONCOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 40: GLOBAL ONCOLOGY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 41: GLOBAL PRENATAL MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 42: GLOBAL PRENATAL MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 43: GLOBAL OTHERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 44: GLOBAL OTHERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 45: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 46: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 47: GLOBAL HOSPITALS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 48: GLOBAL HOSPITALS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 49: GLOBAL CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 50: GLOBAL CLINICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 51: GLOBAL DIAGNOSTIC CENTRES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 52: GLOBAL DIAGNOSTIC CENTRES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 53: GLOBAL OTHERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 54: GLOBAL OTHERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 55: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 56: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 57: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 58: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 59: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 60: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 61: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 62: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 63: REST OF WORLD MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 64: REST OF WORLD MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

FIGURE LIST          

FIGURE 1: KEY INVESTMENT INSIGHTS

FIGURE 2: PORTER’S FIVE FORCE ANALYSIS

FIGURE 3: VALUE PROPOSITION – LABORATORY, IMMUNOASSAY, AND MOLECULAR POC DIAGNOSTIC

FIGURE 4: OPPORTUNITY MATRIX

FIGURE 5: VENDOR LANDSCAPE

FIGURE 6: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2018

FIGURE 7: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2019-2028 (IN $ MILLION)

FIGURE 8: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL BY PCR TECHNOLOGY, IN 2018

FIGURE 9: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY REAL TIME PCR, 2019-2028 (IN $ MILLION)

FIGURE 10: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIGITAL PCR, 2019-2028 (IN $ MILLION)

FIGURE 11: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, 2019-2028 (IN $ MILLION)

FIGURE 12: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHER, 2019-2028 (IN $ MILLION)

FIGURE 13: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2018

FIGURE 14: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ASSAYS, 2019-2028 (IN $ MILLION)

FIGURE 15: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INSTRUMENTS, 2019-2028 (IN $ MILLION)

FIGURE 16: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SOFTWARE, 2019-2028 (IN $ MILLION)

FIGURE 17: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2018

FIGURE 18: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, 2019-2028 (IN $ MILLION)

FIGURE 19: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY INFECTIOUS DISEASE, IN 2018

FIGURE 20: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY RESPIRATORY, 2019-2028 (IN $ MILLION)

FIGURE 21: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITAL ACQUIRED INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 22: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY SEXUALLY TRANSMITTED INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 23: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY GASTRO INTESTINAL INFECTIONS, 2019-2028 (IN $ MILLION)

FIGURE 24: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY ONCOLOGY, 2019-2028 (IN $ MILLION)

FIGURE 25: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRENATAL, 2019-2028 (IN $ MILLION)

FIGURE 26: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 27: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2018

FIGURE 28: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY HOSPITALS, 2019-2028 (IN $ MILLION)

FIGURE 29: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY CLINICS, 2019-2028 (IN $ MILLION)

FIGURE 30: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY DIAGNOSTIC CENTRES, 2019-2028 (IN $ MILLION)

FIGURE 31: GLOBAL MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY OTHERS, 2019-2028 (IN $ MILLION)

FIGURE 32: NORTH AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028  (IN %)

FIGURE 33: UNITED STATES MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 34: CANADA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 35: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028  (IN %)

FIGURE 36: UNITED KINGDOM MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 37: GERMANY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 38: FRANCE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 39: ITALY MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 40: RUSSIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 41: BELGIUM MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 42: POLAND MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 43: REST OF EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 44: ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028  (IN %)

FIGURE 45: CHINA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 46: JAPAN MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 47: INDIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 48: SOUTH KOREA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 49: INDONESIA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 50: THAILAND MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 51: VIETNAM MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 52: AUSTRALIA & NEW ZEALAND MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 53: REST OF ASIA PACIFIC MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION

FIGURE 54: REST OF WORLD MOLECULAR POINT OF CARE MARKET, REGIONAL OUTLOOK, 2019 & 2028  (IN %)

FIGURE 55: LATIN AMERICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 56: MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

  1. MARKET BY TECHNOLOGY
    •    POLYMERASE CHAIN REACTION
      • REAL TIME PCR
      • DIGITAL PCR
    • ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    • OTHER
  2. MARKET BY PRODUCT
    • ASSAYS
    • INSTRUMENTS
    • SOFTWARE
  3. MARKET BY APPLICATION
    •    INFECTIOUS DISEASE
      • RESPIRATORY
      • HOSPITAL ACQUIRED INFECTIONS
      • SEXUALLY TRANSMITTED INFECTIONS
      • GASTRO INTESTINAL INFECTIONS
    • ONCOLOGY
    • PRENATAL
    • OTHERS
  4. MARKET BY END-USER
    • HOSPITALS
    • CLINICS
    • DIAGNOSTICS CENTRES
    • OTHERS
  5. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • UNITED STATES
      • CANADA
    •    EUROPE
      • UNITED KINGDOM
      • GERMANY
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • SOUTH KOREA
      • INDONESIA
      • THAILAND
      • VIETNAM
      • AUSTRALIA & NEW ZEALAND
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    Choose License Type

    Buy Now